- Previous Close
209.29 - Open
210.90 - Bid --
- Ask --
- Day's Range
206.10 - 210.92 - 52 Week Range
196.10 - 472.80 - Volume
644,648 - Avg. Volume
631,547 - Market Cap (intraday)
67.555B - Beta (5Y Monthly) 0.85
- PE Ratio (TTM)
-- - EPS (TTM)
-11.95 - Earnings Date Nov 4, 2024 - Nov 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1,282.00
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company's products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson's disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer's disease. Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.
www.sparc.life409
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: SPARC.NS
View MorePerformance Overview: SPARC.NS
Trailing total returns as of 10/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SPARC.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SPARC.NS
View MoreValuation Measures
Market Cap
67.95B
Enterprise Value
67.00B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
99.26
Price/Book (mrq)
54.01
Enterprise Value/Revenue
97.94
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
684.05M
Net Income Avi to Common (ttm)
-3.88B
Diluted EPS (ttm)
-11.95
Balance Sheet and Cash Flow
Total Cash (mrq)
1.57B
Total Debt/Equity (mrq)
48.63%
Levered Free Cash Flow (ttm)
--